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Abstract
Background: There has been an increased trend towards 
the legalisation of medicinal and recreational cannabis use 
worldwide. This has been controversial as the long-term 
effects of frequent cannabis use on the brain are still poorly 
understood. 
Methods: In this study, we investigated whether the legal status 
of cannabis in the United States of America (USA) is associated 
with problematic cannabis use and impulsivity in 329 frequent 
cannabis users. The data were collected in 2015 and were 
analysed in 2017. Ethical approval for this study was obtained 
from Monash University in 2015.
Results: The results indicated that participants’ problematic 
cannabis use and impulsivity was not different whether they 
resided in states where cannabis is legal for medical and/or 
recreational use or prohibited.
Limitations: The present study is a cross-sectional design, making 
it difficult to infer causality and establish whether cannabis use is a 
cause, consequence, or correlate of altered impulsivity. 
Conclusion: Our study supports the notion that frequent 
cannabis use is associated with impulsive behaviours, whilst, 
conversely, we did not find an association between US state 
legalisation and problematic cannabis use or impulsivity. 
Keywords: impulsivity, legal status of cannabis in the USA, 
problematic cannabis use.
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Introduction
Following the Single Convention on Narcotic Drugs in 1961, 
recreational cannabis use was banned and its possession 
became criminalised.1 Thereafter, cannabis-related crimes – 
including use and possession – increased dramatically in 
the USA and Europe, particularly amongst young people.1 A 
decade later, concerns were raised regarding the detrimental 
effects of criminal records on young people.2 Consequently, 
some US states decriminalised cannabis use in the 1970s and 
replaced imprisonment with fines.2 To date, across the USA, 
cannabis has been legalised by 29 states for medical use and 
8 states for both recreational and medical use. Yet, evidence 
suggests an association between frequent cannabis use and 
dependence, cognitive impairment, and vulnerability to 
psychotic illness.3 Further evidence suggests that adolescent 
cannabis users are at a greater risk for adverse outcomes, 
including persistent cognitive impairment and increased risk 
of psychotic symptoms.4 A primary public health concern has 
been to establish whether the legalisation of cannabis is likely 
to increase use amongst youth with concomitant negative 
consequences. Studies show mixed results; some have found 
higher rates of cannabis use in states that have legalised 
medicinal use,5 whereas others have found no difference after 
law enactment in the USA.6 MacCoun7 compared cannabis use 
in the USA and Netherlands after the legalisation of cannabis 
and found that cannabis use amongst students aged 15–16 
years was higher in the USA. Other countries in the EU that 
have not legalised cannabis either matched or exceeded the 
rate of students’ cannabis use in the Netherlands.7 These 
studies suggest that legalising cannabis for recreational and/
or medical purposes does not necessarily lead to an increase 
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in cannabis use. Other studies show that cannabis use affects 
regulatory networks of the brain and is associated with 
impulsivity.8 For example, it was demonstrated that cannabis 
increased impulsivity immediately after administration9; 
changes in impulsivity due to cannabis consumption may 
interfere with individuals’ self-regulation, leading to risky 
or problematic behaviours.10 As the cannabis landscape 
evolves and governments are increasingly turning towards 
legalisation, the public health concerns around cannabis use 
warrant further research. In the present study, we investigated 
whether there was an association between legalisation status 
and either problematic cannabis use or impulsivity in frequent 
cannabis users and whether the legal status of cannabis in 
the USA moderates the association between impulsivity and 
problematic use. 
Methods
Ethical approval for this study was obtained from Monash 
University Human Research Ethics Committee (project number: 
CF15/1235 – 2015000576). 329 frequent cannabis users were 
recruited online via the Amazon Mechanical Turk (https://
www.mturk.com/) in 2015, and gave informed consent prior 
to commencing the questionnaire. All participants were 
US residents and frequent cannabis use was defined as 
having used cannabis once or more per week for the past 12 
months (mean consumption: 3.93, s.d.: 2.34 times per week). 
Participants indicated that they had no history of diagnosed 
alcohol or other illicit substance disorders and that they had 
not used illicit substances other than cannabis once a month or 
more across the past 12 months. The sample consisted of 196 
males and 133 females. The majority were Caucasian (82%)  
(see Table 1 for descriptive statistics.)
The Cannabis Use Problems Identification Test (CUPIT) was used 
to assess problematic cannabis use. It is a 16-item self-report 
scale with two subscales: ‘Impaired Control’ over cannabis use 
and ‘Problems’ caused by or as a consequence of cannabis 
use.11 About 95% of participants met criteria for being at risk 
of developing a cannabis use disorder, as indicated by scores 
above 12. About 73% of participants met criteria for cannabis 
use disorder as indicated by scores above 20.11 The Barratt 
Impulsiveness Scale was used to assess how often individuals 
perform different behaviours. US state legalisation status was 
obtained in 2015, and individuals were classified into two 
groups: states where cannabis use was legal for recreational 
and/or medical purposes (n=158) and states where cannabis 
was prohibited (n=171) (see Figure 1).
The association between legalisation status and problematic 
cannabis use (i.e. ‘Impaired Control’ and ‘Problems’) and 
impulsivity were examined using a series of one-way analyses 
of variance (ANOVA). To examine whether the relationship 
between impulsivity and problematic cannabis use was 
moderated by legalisation status, we used multiple regressions. 
Problematic cannabis use was regressed on impulsivity, 
legalisation status, the interaction between impulsivity and 
legalisation status, and a vector of control variables (age, gender, 
and ethnicity [defined by ‘Caucasian’ or ‘other’]). Statistical 
analyses were performed using IBM SPSS Statistics version 23.
Results
A series of ANOVA found no association between state 
legalisation status and CUPIT ‘Impaired Control’ subscale, CUPIT 
‘Problems’ subscale, or impulsivity (see Figure 2). The three 
ANOVA analyses were replicated using a subset of the sample 
that comprised only the 73% of individuals who met criteria for a 
Figure 1. Legalisation status of cannabis use in the USA in 2015.
Cannabis is legal for recreational and/or medical use
Cannabis is prohibited
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Table 1. Demographic and clinical characteristics of participants.
Variable Total (n=329) Cannabis legal for medical  
and/or recreational use  
(n=158)
Cannabis is  
prohibited (n=171)
Gender (%) M: 196 (59.6%)
F: 133 (40.4%)
M: 101 (63.9%)
F: 57 (36.1%)
M: 95 (55.6%)
F: 76 (44.4%)
Age – Mean (SD) M: 25.83 (3.27)
F: 26.12 (3.31) 25.67 (3.24) 26.20 (3.32)
Ethnicity (%)
     Caucasian n=270 (82.1%) n=126 (79.7%) n=144 (84.2%)
     Other n=59 (17.9%) n=32 (20.3%) n=27 (15.8%)
CUPIT ‘Impaired  
Control’ – Mean (SD)
24.54 (9.15) 24.56 (9.17) 24.53 (9.16)
CUPIT ‘Problems’ –  
Mean (SD)
3.03 (3.04) 3.30 (3.33) 2.77 (2.72)
BIS-11 – Mean (SD) 59.21 (11.60) 59.88 (10.87) 58.60 (12.25)
BIS-11, Barratt Impulsiveness Scale; CUPIT, The Cannabis Use Problems Identification Test; F, female; M, male; SD, 
standard deviation.
Figure 2. CUPIT and Barrat Impulsivity Scale 
scores for both groups; cannabis legal 
for recreational and/or medical purposes 
and cannabis is prohibited. 
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cannabis use disorder; however, again there was no association 
between state legalisation status and any of the three outcome 
variables. Two linear multiple regression models (Table 2) 
were then used to examine whether the relationship between 
impulsivity and problematic cannabis use was moderated 
by legalisation status. Specifically, these models regressed 
the outcome variables (i.e. ‘Impaired Control’ and ‘Problems’) 
on impulsivity, legalisation status, the interaction between 
impulsivity and legalisation status, and a vector of control 
variables. These models were found to explain 8% and 17% of 
the variance in problematic cannabis use when using ‘Impaired 
Control’ and ‘Problems’ subscales as the dependent variables, 
respectively. Results from the regression models found that after 
adjustment, impulsivity predicted ‘Impaired Control’ (β=0.24, 
p=0.001) as well as ‘Problems’ (β=0.34, p<0.001). However, the 
interaction between impulsivity and legalisation status was 
not significant in both models suggesting that the relationship 
between impulsivity and problematic cannabis use was not 
different depending on legalisation status. 
Discussion
These data indicate that there is a positive association between 
problematic cannabis use and impulsivity in frequent cannabis 
users. This finding is in accord with other studies showing 
an association between problematic cannabis use and 
impulsivity.9 A strong body of research shows that cannabis use 
is linked with impulsivity, and studies suggest that impulsivity 
is an important factor related to the early stages of addiction 
processes, such as drug experimentation.10 Our results also 
show that legalisation status in the USA is not associated with 
problematic cannabis use and impulsivity. The current findings 
go beyond prior studies to suggest that, at this point in time, 
the legalisation status of cannabis has not shown an association 
with cannabis use amongst frequent users, a finding supported 
by a growing body of literature.6 Although the detrimental 
health effects of frequent cannabis use are well established,3 
our findings suggest that legalisation status does not worsen 
these effects. It is too early to conclude that the legal status 
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are common in frequent cannabis users.12,13 Notwithstanding, all 
participants were informed that their responses would remain 
anonymous and confidential, encouraging genuine responses. 
Furthermore, studies have reported that using self-reports are 
relatively valid tools to measure cannabis use, even compared to 
more objective measures such as urine tests.14,15 Nonetheless, it 
should be noted that we cannot exclude the influence of biases 
on the accuracy of this study’s results.
Conclusion
Despite the above limitations, our study supports the notion 
that frequent cannabis use is associated with impulsive 
behaviours, whilst, conversely, we did not find an association 
between US state legalisation and problematic cannabis use 
or impulsivity. These findings contribute to the debate related 
to the benefits of legalising cannabis use and contribute to 
the debate over the link between problematic cannabis use 
and state legalisation status as well as impulsive behaviours.
of cannabis in the USA has had no effects on problematic 
cannabis use or cannabis-related harms, especially in states 
with liberal definitions of cannabis use.2 
Limitations of the study
Our study has several limitations. First, it uses cross-sectional 
data, making it difficult to infer causality and establish whether 
cannabis use is a cause, consequence, or correlate of altered 
impulsivity. Future research would benefit from a longitudinal 
design to track over the long term whether there is an association 
between legalisation status of cannabis and problem use and 
impulsivity. A second limitation is the small sample size, which 
restricted our ability to investigate those using cannabis for 
recreational purposes only compared with both recreational and 
medical purposes. A third limitation is the recruitment design 
that relied on online self-report data, which may lead to biases. 
For instance, participants may not have reported their cannabis 
use or impulsivity accurately due to memory impairments, which 
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Table 2. Multiple regression analysis for variables predicting problematic cannabis use.
Variable b 95% Confidence interval p-value Standardised β
Regression 1: Impaired Control subscale as DV
BIS-11 total score 0.19 0.08; 0.30 0.001* 0.24
Legal vs Illegal −0.95 −11.22; 9.32 0.86 −0.05
BIS-11 × Legalisation 0.01 −0.16; 0.18 0.90 0.04
Ethnicity 1.38 −1.16; 3.92 0.29 0.06
Age 0.08 −0.22; 0.38 0.60 0.03
Gender −1.90 −3.89; 0.07 0.06 −0.10
R-squared 0.08
N 329
Regression 2: CUPIT Problems subscale as DV
BIS-11 total score 0.09 0.06; 0.12 <0.001* 0.34
Legal vs Illegal −1.14 −4.36; 2.09 0.49 −0.19
BIS-11 × Legalisation 0.03 −0.03; 0.08 0.36 0.26
Ethnicity 0.48 −0.31; 1.29 0.23 0.06
Age −0.03 −0.12; 0.07 0.60 −0.03
Gender −0.59 −1.21; 0.04 0.07 −0.10
R-squared 0.17
N 329
*p<0.05.
DV, dependent variable.
ORIGINAL RESEARCH – Legalisation status of cannabis and problematic cannabis use and impulsivity in the USA drugsincontext.com
Destrée L, Amiet D, Carter A, Lee R, Lorenzetti V, Segrave R, Youssef G, Solowij N, Yücel M. Drugs in Context 2018; 7: 212541. DOI: 10.7573/dic.212541 5 of 5
ISSN: 1740-4398
References
1. Room R, Fisher B, Hall W, Lenton S, Reuter P. Cannabis Policy: Moving Beyond Stalemate. USA (New York): Oxford University 
Press; 2010.
2. Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther. 
2015;97(6):607–615. https://doi.org/10.1002/cpt.110
3. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–2227. 
https://doi.org/10.1056/NEJMra1402309
4. Gruber SA, Dahlgren MK, Sagar KA, Gönenç A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter 
and impulsivity. Psychopharmacology. 2014;231(8):1455–1465. https://doi.org/10.1007/s00213-013-3326-z.
5. Cerdá M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state 
legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120(1):22–27.  
https://doi.org/10.1016/j.drugalcdep.2011.06.011
6. Choo EK, Benz M, Zaller N, Warren O, Rising KL, McConnell KJ. The impact of state medical marijuana legislation on adolescent 
marijuana use. J Adolesc Health. 2014;55(2):160–166. https://doi.org/10.1016/j.jadohealth.2014.02.018
7. MacCoun RJ. What can we learn from the Dutch cannabis coffeeshop system? Addiction. 2011;106(11):1899–1910.  
https://doi.org/10.1111/j.1360-0443.2011.03572.x
8. Wrege J, Schmidt A, Walter A, et al. Effects of cannabis on impulsivity: a systematic review of neuroimaging findings. Curr Pharm 
Des. 2014;20(13):2126–2137. https://doi.org/10.2174/13816128113199990428
9. McDonald J, Schleifer L, Richards JB, de Wit H. Effects of THC on behavioural measures of impulsivity in humans. 
Neuropsychopharmacoogy. 2003;28(7):1356. https://doi.org/10.1038/sj.npp.1300176
10. Ansell EB, Laws HB, Roche MJ, Sinha R. Effects of marijuana use on impulsivity and hostility in daily life. Drug Alcohol Depend. 
2015;148:136–142. https://doi.org/10.1016/j.drugalcdep.2014.12.029
11. Bashford J, Flett R, Copeland J. The cannabis use problems identification test (CUPIT): development, reliability, concurrent and 
predictive validity among adolescents and adults. Addiction. 2010;105(4):615–625. https://doi.org/10.1111/j.1360-0443.2009.02859.x
12. Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 
2006;188(4):425–444. https://doi.org/10.1007/s00213-006-0508-y
13. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Current Drug Abuse Rev. 2008;1(1):81–98. 
https://doi.org/10.2174/1874473710801010081
14. Basurto FZ, Montes JMG, Cubos PF, Santed FS, Ríos FL, Moreno AM. Validity of the self-report on drug use by university students: 
correspondence between self-reported use and use detected in urine. Psicothema. 2009;21(2):213–219.
15. Mayet A, Esvan M, Marimoutou C, et al. The accuracy of self-reported data concerning recent cannabis use in the French armed 
forces. Eur J Public Health. 2012;23(2):328–332. https://doi.org/10.1093/eurpub/cks108
Funding declaration: Professor Murat Yücel was supported by a National Health and Medical Research Council of Australia Fellowship 
(#APP1117188) and the David Winston Turner Endowment Fund. There was no other funding associated with the preparation of this article.
Copyright: Copyright © 2018 Destrée L, Amiet D, Carter A, Lee R, Lorenzetti V, Segrave R, Youssef G, Solowij N, Yücel M. Published by Drugs in 
Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is 
properly attributed in the manner specified below. No commercial use without permission. 
Correct attribution: Copyright © 2018 Destrée L, Amiet D, Carter A, Lee R, Lorenzetti V, Segrave R, Youssef G, Solowij N, Yücel M.  
https://doi.org/10.7573/dic.212541. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0. 
Article URL: https://www.drugsincontext.com/exploring-the-association-of-legalisation-status-of-cannabis-with-problematic-cannabis-use-
and-impulsivity-in-the-usa
Correspondence: Murat Yücel, Monash Institute of Cognitive & Clinical Neuroscience, 1st floor, Monash Biomedical Imaging, 770 Blackburn 
Road, Clayton, Victoria 3800, Australia. murat.yucel@monash.edu
Provenance: submitted; externally peer reviewed.
Submitted: 20 June 2018; Peer review comments to author: 25 July 2018; Revised manuscript received: 6 August 2018; Accepted: 7 August 
2018; Publication date: 17 September 2018.
Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.
BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07. 
For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com 
For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com
